Immune cell responses are not required to induce substantial hepatitis B virus antigen decline during pegylated interferon-alpha administration

Journal of Hepatology

Volumn 60, Issue 3, 2014, Pages 500-507

  Allweiss, Lena ^a   Volz, Tassilo ^a   Lütgehetmann, Marc ^a   Giersch, Katja ^a   Bornscheuer, Till ^a   Lohse, Ansgar W ^a,b   Petersen, Joerg ^c   Ma, Han ^d   Klumpp, Klaus ^d   Fletcher, Simon P ^d   Dandri, Maura ^a,b  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b German Center for Infection Research   (Germany)

^c DEPARTMENT OF CARDIOLOGY   (Germany)

^d HOFFMANN LA ROCHE INC   (United States)

Author keywords

cccDNA; HBeAg; HBsAg; Hepatocyte responsiveness; Humanized mice; Interferon stimulated genes

Indexed keywords

ALPHA INTERFERON; ANTIVIRUS AGENT; ENTECAVIR; GUANINE; HEPATITIS B SURFACE ANTIGEN; MACROGOL DERIVATIVE; PEGINTERFERON ALPHA2B; RECOMBINANT PROTEIN; VIRUS DNA;

ANALOGS AND DERIVATIVES; ANIMAL; BLOOD; HEPATITIS B, CHRONIC; HUMAN; IMMUNOLOGY; LIVER CELL; MOUSE; VIROLOGY;

ANIMALS; ANTIVIRAL AGENTS; DNA, VIRAL; GUANINE; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B, CHRONIC; HEPATOCYTES; HUMANS; INTERFERON-ALPHA; MICE; POLYETHYLENE GLYCOLS; RECOMBINANT PROTEINS;

EID: 84894064916     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhep.2013.10.021     Document Type: Article

References (39)

1. M. Dandri, and S. Locarnini New insight in the pathobiology of hepatitis B virus infection Gut 61 2012 i6 i17
2. M. Levrero, T. Pollicino, J. Petersen, L. Belloni, G. Raimondo, and M. Dandri Control of cccDNA function in hepatitis B virus infection J Hepatol 51 2009 581 592
3. T. Pollicino, L. Belloni, G. Raffa, N. Pediconi, G. Squadrito, and G. Raimondo et al. Hepatitis B virus replication is regulated by the acetylation status of hepatitis B virus cccDNA-bound H3 and H4 histones Gastroenterology 130 2006 823 837
4. T. Lang, C. Lo, N. Skinner, S. Locarnini, K. Visvanathan, and A. Mansell The hepatitis B e antigen (HBeAg) targets and suppresses activation of the toll-like receptor signaling pathway J Hepatol 55 2011 762 769
5. M.L. Op den Brouw, R.S. Binda, M.H. van Roosmalen, U. Protzer, H.L. Janssen, and R.G. van der Molen et al. Hepatitis B virus surface antigen impairs myeloid dendritic cell function: a possible immune escape mechanism of hepatitis B virus Immunology 126 2009 280 289
6. S. Chevaliez, C. Hezode, S. Bahrami, M. Grare, and J.M. Pawlotsky Long-term hepatitis B surface antigen (HBsAg) kinetics during nucleoside/nucleotide analogue therapy: finite treatment duration unlikely J Hepatol 58 2013 676 683
7. K. Wursthorn, M. Lutgehetmann, M. Dandri, T. Volz, P. Buggisch, and B. Zollner et al. Peginterferon alpha-2b plus adefovir induce strong cccDNA decline and HBsAg reduction in patients with chronic hepatitis B Hepatology 44 2006 675 684
8. M.R. Brunetto, F. Moriconi, F. Bonino, G.K. Lau, P. Farci, and C. Yurdaydin et al. Hepatitis B virus surface antigen levels: a guide to sustained response to peginterferon alfa-2a in HBeAg-negative chronic hepatitis B Hepatology 49 2009 1141 1150
9. P. Lampertico, and Y.F. Liaw New perspectives in the therapy of chronic hepatitis B Gut 61 2012 i18 i24
10. R. Moucari, V. Mackiewicz, O. Lada, M.P. Ripault, C. Castelnau, and M. Martinot-Peignoux et al. Early serum HBsAg drop: a strong predictor of sustained virological response to pegylated interferon alfa-2a in HBeAg-negative patients Hepatology 49 2009 1151 1157
11. J.J. Sung, M.L. Wong, S. Bowden, C.T. Liew, A.Y. Hui, and V.W. Wong et al. Intrahepatic hepatitis B virus covalently closed circular DNA can be a predictor of sustained response to therapy Gastroenterology 128 2005 1890 1897
12. D.K. Wong, M.F. Yuen, V.W. Ngai, J. Fung, and C.L. Lai One-year entecavir or lamivudine therapy results in reduction of hepatitis B virus intrahepatic covalently closed circular DNA levels Antivir Ther 11 2006 909 916
13. M.J. Sonneveld, R. Zoutendijk, B.E. Hansen, and H.L. Janssen Pegylated interferon results in higher serological, but not virological, response rates when compared to continuous entecavir Antivir Ther 17 2012 1605 1608
14. EASL clinical practice guidelines Management of chronic hepatitis B virus infection J Hepatol 57 2012 167 185
15. H.L. Chan, A. Thompson, M. Martinot-Peignoux, T. Piratvisuth, M. Cornberg, and M.R. Brunetto et al. Hepatitis B surface antigen quantification: why and how to use it in 2011 - a core group report J Hepatol 55 2011 1121 1131
16. R. Thimme, and M. Dandri Dissecting the divergent effects of interferon-alpha on immune cells: time to rethink combination therapy in chronic hepatitis B? J Hepatol 58 2013 205 209
17. A. Bertoletti, and C. Ferrari Innate and adaptive immune responses in chronic hepatitis B virus infections: towards restoration of immune control of viral infection Gut 61 2012 1754 1764
18. M. Lutgehetmann, T. Volzt, A. Quaas, M. Zankel, C. Fischer, and M. Dandri et al. Sequential combination therapy leads to biochemical and histological improvement despite low ongoing intrahepatic hepatitis B virus replication Antivir Ther 13 2008 57 66
19. S.F. Wieland, A. Eustaquio, C. Whitten-Bauer, B. Boyd, and F.V. Chisari Interferon prevents formation of replication-competent hepatitis B virus RNA-containing nucleocapsids Proc Natl Acad Sci U S A 102 2005 9913 9917
20. C. Xu, H. Guo, X.B. Pan, R. Mao, W. Yu, and X. Xu et al. Interferons accelerate decay of replication-competent nucleocapsids of hepatitis B virus J Virol 84 2010 9332 9340
21. L. Belloni, L. Allweiss, F. Guerrieri, N. Pediconi, T. Volz, and T. Pollicino et al. IFN-alpha inhibits HBV transcription and replication in cell culture and in humanized mice by targeting the epigenetic regulation of the nuclear cccDNA minichromosome J Clin Invest 122 2012 529 537
22. M. Lutgehetmann, T. Bornscheuer, T. Volz, L. Allweiss, J.H. Bockmann, and J.M. Pollok et al. Hepatitis B virus limits response of human hepatocytes to interferon-alpha in chimeric mice Gastroenterology 140 2011 2074 2083
23. T. Volz, M. Lutgehetmann, P. Wachtler, A. Jacob, A. Quaas, and J.M. Murray et al. Impaired intrahepatic hepatitis B virus productivity contributes to low viremia in most HBeAg-negative patients Gastroenterology 133 2007 843 852
24. K. Wursthorn, M. Jung, A. Riva, Z.D. Goodman, P. Lopez, and W. Bao et al. Kinetics of hepatitis B surface antigen decline during 3 years of telbivudine treatment in hepatitis B e antigen-positive patients Hepatology 52 2010 1611 1620
25. K. Inoue, T. Umehara, U.T. Ruegg, F. Yasui, T. Watanabe, and H. Yasuda et al. Evaluation of a cyclophilin inhibitor in hepatitis C virus-infected chimeric mice in vivo Hepatology 45 2007 921 928
26. M. Dandri, and J. Petersen Chimeric mouse model of hepatitis B virus infection J Hepatol 56 2012 493 495
27. T. Watanabe, F. Sugauchi, Y. Tanaka, K. Matsuura, H. Yatsuhashi, and S. Murakami et al. Hepatitis C virus kinetics by administration of pegylated interferon-alpha in human and chimeric mice carrying human hepatocytes with variants of the IL28B gene Gut 62 2013 1340 1346
28. M. Sarasin-Filipowicz, X. Wang, M. Yan, F.H. Duong, V. Poli, and D.J. Hilton et al. Alpha interferon induces long-lasting refractoriness of JAK-STAT signaling in the mouse liver through induction of USP18/UBP43 Mol Cell Biol 29 2009 4841 4851
29. J. Li, K. Liu, Y. Liu, Y. Xu, F. Zhang, and H. Yang et al. Exosomes mediate the cell-to-cell transmission of IFN-alpha-induced antiviral activity Nat Immunol 14 2013 793 803
30. A. Penna, D. Laccabue, I. Libri, T. Giuberti, S. Schivazappa, and A. Alfieri et al. Peginterferon-alpha does not improve early peripheral blood HBV-specific T-cell responses in HBeAg-negative chronic hepatitis J Hepatol 56 2012 1239 1246
31. L. Micco, D. Peppa, E. loggi, A. Schurich, L. Jefferson, and C. Cursaro et al. Differential boosting of innate and adaptive antiviral responses during pegylated-interferon-alpha therapy of chronic hepatitis B J Hepatol 58 2013 225 233
32. N. Li, Q. Li, Z. Qian, Y. Zhang, M. Chen, and G. Shi Impaired TLR3/IFN-beta signaling in monocyte-derived dendritic cells from patients with acute-on-chronic hepatitis B liver failure: relevance to the severity of liver damage Biochem Biophys Res Commun 390 2009 630 635
33. J. Wu, Z. Meng, M. Jiang, R. Pei, M. Trippler, and R. Broering et al. Hepatitis B virus suppresses toll-like receptor-mediated innate immune responses in murine parenchymal and nonparenchymal liver cells Hepatology 49 2009 1132 1140
34. A. Das, M. Hoare, N. Davies, A.R. Lopes, C. Dunn, and P.T. Kennedy et al. Functional skewing of the global CD8 T cell population in chronic hepatitis B virus infection J Exp Med 205 2008 2111 2124
35. C. Boni, P. Fisicaro, C. Valdatta, B. Amadei, P. Di Vincenzo, and T. Giuberti et al. Characterization of hepatitis B virus (HBV)-specific T-cell dysfunction in chronic HBV infection J Virol 81 2007 4215 4225
36. A.T. Tan, L.T. Hoang, D. Chin, E. Rasmussen, U. Lopatin, and S. Hart et al. Reduction of HBV replication prolongs the early immunological response to IFNalpha therapy J Hepatol 2013 10.1016/j.jhep.2013.08.020 [Epub ahead of print]
37. M.J. Sonneveld, V. Rijckborst, Y. Cakaloglu, K. Simon, E.J. Heathcote, and F. Tabak Durable hepatitis B surface antigen decline in hepatitis B e antigen-positive chronic hepatitis B patients treated with pegylated interferon-alpha2b: relation to response and HBV genotype Antivir Ther 17 2012 9 17
38. V. Rijckborst, B.E. Hansen, P. Ferenci, M.R. Brunetto, F. Tabak, and Y. Cakaloglu et al. Validation of a stopping rule at week 12 using HBsAg and HBV DNA for HBeAg-negative patients treated with peginterferon alfa-2a J Hepatol 56 2012 1006 1011
39. D. Ge, J. Fellay, A.J. Thompson, J.S. Simon, K.V. Shianna, and T.J. Urban et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance Nature 461 2009 399 401